|
|
|
| Effect of Nimesulide Combined with Loxofen Sodium on TIMP-1 MMP-3 and Bone Metabolic Indexes in Patients with Knee Osteoarthritis |
| LI Bo, BAI Ningjuan |
| The First Affiliated Hospital of Air Force Medical University, Shaanxi Xian 710000, China |
|
|
|
|
Abstract Objective: To investigate the effects of nimesulide combined with loxofen sodium on TIMP-1, MMP-3 and bone metabolism in patients with knee osteoarthritis. Methods: From January 2019 to September 2021, 92 patients with knee osteoarthritis were included in this study as the observation subjects and divided into control group (n=46) and combined group (n=46) according to the randomized-control principle. The control group was given loxofen sodium. The combined group was given nimesulide combined with loxofen sodium both group for 4 weeks as a course of treatment. All patients completed the treatment and were followed up. The efficacy of the two groups was evaluated at the end of the 4-week course of treatment. The serum levels of matrix metalloproteinase 3 (MMP-3), matrix metalloproteinase inhibitor 1 (TIMP-1), osteocalcin (BGP) and osteoprotegerin (OPG) were measured before and after treatment, and the adverse reactions were recorded. Results: The total effective rate of the control group was 82.61% (38/46), which was lower than that of observation group 95.65% (44/46), and the difference was statistically significant (P<0.05). Compared with before treatment, serum MMP-3 decreased and serum TIMP-1 increased in the two groups after 4 weeks of treatment, the difference of serum MMP-3 and TIMP-1 before and after treatment was statistically significant (P<0.05). Compared with before treatment,the serum BGP and OPG levels increased in both groups after 4 weeks of treatment. The difference of serum BGP and OPG levels before and after treatment between the two groups was statistically significant (P<0.05).There was no statistical significance in the adverse reaction rate between the two groups (P>0.05). Conclusion: Nimesulide combined with loxofen sodium can improve the treatment efficacy among knee osteoarthritis patients, improve bone metabolism and matrix metalloprotein level with high safety.
|
|
|
|
|
|
[1] Katz J N,Arant K R,Loeser R F.Diagnosis and treatment of hip and knee osteoarthritis:a review[J].Jama,2021,325(6):568-578.
[2] 戴守达,陈刚,周正顺.膝骨性关节炎药物治疗进展[J].医学综述,2020,26(2):331-335.
[3] 中华医学会骨科学分会关节外科学组.骨关节炎诊疗指南(2018年版)[J].中华骨科杂志,2018,38(12):705-715.
[4] Arden N K,Perry T A,Bannuru R R,et al.Non-surgical management of knee osteoarthritis:comparison of ESCEO and OARSI 2019 guidelines[J].Nature Reviews Rheumatology,2021,17(1):59-66.
[5] Jones I A,Togashi R,Wilson M L,et al.Intra-articular treatment options for knee osteoarthritis[J].Nature Reviews Rheumatology,2019,15(2):77-90.
[6] Sharma L.Osteoarthritis of the knee[J].New England Journal of Medicine,2021,384(1):51-59.
[7] 江志勇,许楚宏,陈海燕,等.新型非甾体抗炎药洛索洛芬钠治疗膝骨关节炎的临床效果观察[J].海峡药学,2019,31(1):160-161.
[8] 樊文良.尼美舒利联合双醋瑞因治疗膝骨性关节炎的临床疗效分析[J].北方药学,2018,15(9):64-65.
[9] 熊明月,鲁学良,刘振辉,等.尼美舒利联合双醋瑞因治疗膝骨性关节炎的临床研究[J].现代药物与临床,2017,32(1):84-87.
[10] 漆继聪,喻丹.尼美舒利联合双醋瑞因对膝骨性关节炎患者VAS评分及炎性因子的影响[J].中外医学研究,2020,18(9):24-26.
[11] 陈华炎,潘裕华,陶一鸣,等.临床药师参与1例尼美舒利致急性肾损伤的临床实践[J].今日药学,2019,29(9):633-635.
[12] 黄远,刘日光,张沕,等.膝关节骨关节炎相关炎症及软骨代谢标志物的表达与临床意义[J].中国骨质疏松杂志,2021,27(11):1614-1619,1625. |
|
|
|
2023, Vol. 29 
